ViaCyte to Present at IDF World Diabetes Congress 2015
SAN DIEGO, November 17, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced a company presentation at the International Diabetes Federation (IDF) World Diabetes Congress 2015, which will take place in Vancouver, Canada, November 30 to December 4, 2015.
Details of the presentation are as follows:
Title: Preclinical and Clinical Testing of VC-01™ Product Candidate: Stem Cell-Derived, Macroencapsulated Islet Cell Replacement for Type 1 Diabetes
Speaker: Dr. Kevin D’Amour, Vice President, Research, and Chief Scientific Officer
Date/Time: December 2, 2:30 p.m. – 3:00 p.m. PST
Location: Room 119, Vancouver Convention Centre, Vancouver, BC Canada
Session: Islet transplantation vs. embryonic stem cells: Where does the future lie?
ViaCyte’s VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes. The STEP ONE trial is currently evaluating safety in the first cohort of patients, who are receiving a sub-therapeutic dose.
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goals of no immune suppression required, and a reduced risk of hypoglycemia and diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.